Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …
Read the full story »A focus on disease-specific efforts by pharmaceutical and biotech companies
Read in depth analysis by industry experts on investing opportunities and business strategies
Learn about corporate strategies, positioning and investing opportunities
Stay on top of the industry with our industry news bulletin
Diversify to hedge your investment during economic turbulence
CMOS image sensor (CIS) technology stands on the brink of fulfilling its potential to become the global detector platform of choice for scientific photonics applications that require world class performance in the fields of sensitivity, speed, dynamic range, resolution, and field of view.
| DJIA | 10320.10 | ||
| NASDAQ | 2200.01 | ||
| S&P 500 | 1090.10 |
Leave a comment!